4 unknown, 1 active not recruiting. .
Follow Massimo Falconi: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Optimizing Risk Assessment Through cfDNA in Pancreatic Neuroendocrine Tumors for Clinical Evaluation cfDNA molecular profiling - Pancreatic Neuroendocrine Tumor | Active not recruiting | Massimo Falconi | 30 | 2026-09-12 | 2026-09-16 | |
| Financial Toxicity and Patient-Reported Outcomes in GEP-NEN During Treatment Neuroendocrine Tumors | Unknown | Massimo Falconi | 400 | 2020-08-06 | 2024-03-12 | |
| Patient Reported Outcomes Measures to Predict Pancreatic Surgery Outcomes Pancreatic Cancer, Patient Reported Outcome Measures | Unknown | Massimo Falconi | 560 | 2020-05-07 | 2024-01-18 | |
| Efficacy of Chemopreventive Agents on Disease-free and Overall Survival in Patients With Pancreatic Ductal Adenocarcinoma: The CAOS Study use of targeted drugs such as aspirin, B-Blockers, Metformin, ACE-inhibitors, Statins - Disease Free Survival, Overall Survival | Unknown | Massimo Falconi | 800 | 2019-03-02 | 2024-03-12 | |
| A New Scoring System for Perineural and Vascular Invasion in Pancreatic Cancer Pancreas Cancer | Unknown | Massimo Falconi | 500 | 2015-01-01 | 2024-03-12 |
Pancreatic Neoplasms (3) · Adenoma, Islet Cell (1) · Financial Stress (1) · Neuroendocrine Tumors (1)
Angiotensin-Converting Enzyme Inhibitors (1) · Aspirin (1) · Hydroxymethylglutaryl-CoA Reductase Inhibitors (1) · Metformin (1)
Italy (5)
Daniela Cesana, PhD (1) · Marco Schiavo Lena (1) · Stefano Partelli, MD, PhD (1) · Stefano Partelli, Professor (1)